# A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

> **NCT03314935** · PHASE1,PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 149 (actual)

## Conditions studied

- Biliary Tract Cancer (BTC)
- Colorectal Cancer (CRC)
- Endometrial Cancer
- Gastroesophageal Cancer (GC)
- Ovarian Cancer
- Solid Tumors

## Interventions

- **DRUG:** INCB001158
- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin
- **DRUG:** 5-Fluorouracil
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03314935
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-21
- **Primary completion:** 2022-11-28
- **Final completion:** 2022-11-28
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03314935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03314935, "A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03314935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*